These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31996990)

  • 1. Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.
    Lombardi CM; Ferreira JP; Carubelli V; Anker SD; Cleland JG; Dickstein K; Filippatos G; Lang CC; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Voors A; Metra M
    Clin Res Cardiol; 2020 Aug; 109(8):967-977. PubMed ID: 31996990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
    Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
    Ferreira JP; Metra M; Mordi I; Gregson J; Ter Maaten JM; Tromp J; Anker SD; Dickstein K; Hillege HL; Ng LL; van Veldhuisen DJ; Lang CC; Voors AA; Zannad F
    Eur J Heart Fail; 2019 Jan; 21(1):112-120. PubMed ID: 30338883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
    Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M
    Eur J Heart Fail; 2016 Jun; 18(6):716-26. PubMed ID: 27126231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
    Ouwerkerk W; Zwinderman AH; Ng LL; Demissei B; Hillege HL; Zannad F; van Veldhuisen DJ; Samani NJ; Ponikowski P; Metra M; Ter Maaten JM; Lang CC; van der Harst P; Filippatos G; Dickstein K; Cleland JG; Anker SD; Voors AA
    J Am Coll Cardiol; 2018 Jan; 71(4):386-398. PubMed ID: 29389354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
    Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
    Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Canepa M; Straburzynska-Migaj E; Drozdz J; Fernandez-Vivancos C; Pinilla JMG; Nyolczas N; Temporelli PL; Mebazaa A; Lainscak M; Laroche C; Maggioni AP; Piepoli MF; Coats AJS; Ferrari R; Tavazzi L;
    Eur J Heart Fail; 2018 Jan; 20(1):100-110. PubMed ID: 28949063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.
    Pagnesi M; Adamo M; Sama IE; Anker SD; Cleland JG; Dickstein K; Filippatos GS; Inciardi RM; Lang CC; Lombardi CM; Ng LL; Ponikowski P; Samani NJ; Zannad F; van Veldhuisen DJ; Voors AA; Metra M
    Clin Res Cardiol; 2022 Aug; 111(8):912-923. PubMed ID: 35294624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.
    Kobayashi M; Voors AA; Girerd N; Billotte M; Anker SD; Cleland JG; Lang CC; Ng LL; van Veldhuisen DJ; Dickstein K; Metra M; Duarte K; Rossignol P; Zannad F; Ferreira JP
    Eur J Intern Med; 2020 Jan; 71():62-69. PubMed ID: 31708361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
    Inciardi RM; Pagnesi M; Lombardi CM; Anker SD; Cleland JG; Dickstein K; Filippatos GS; Lang CC; Ng LL; Pellicori P; Ponikowski P; Samani NJ; Zannad F; van Veldhuisen DJ; Solomon SD; Voors AA; Metra M
    Eur J Heart Fail; 2022 Nov; 24(11):2131-2139. PubMed ID: 35748048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.
    Grote Beverborg N; van der Wal HH; Klip IT; Anker SD; Cleland J; Dickstein K; van Veldhuisen DJ; Voors AA; van der Meer P
    JAMA Cardiol; 2019 Jul; 4(7):696-701. PubMed ID: 31188392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Bistola V; Simitsis P; Parissis J; Ouwerkerk W; van Veldhuisen DJ; Cleland JG; Anker SD; Samani NJ; Metra M; Zannad F; Polyzogopoulou E; Keramida K; Farmakis D; Voors AA; Filippatos G
    Eur J Heart Fail; 2021 Jul; 23(7):1170-1181. PubMed ID: 33998113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
    Crespo-Leiro MG; Anker SD; Maggioni AP; Coats AJ; Filippatos G; Ruschitzka F; Ferrari R; Piepoli MF; Delgado Jimenez JF; Metra M; Fonseca C; Hradec J; Amir O; Logeart D; Dahlström U; Merkely B; Drozdz J; Goncalvesova E; Hassanein M; Chioncel O; Lainscak M; Seferovic PM; Tousoulis D; Kavoliuniene A; Fruhwald F; Fazlibegovic E; Temizhan A; Gatzov P; Erglis A; Laroche C; Mebazaa A;
    Eur J Heart Fail; 2016 Jun; 18(6):613-25. PubMed ID: 27324686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
    Maggioni AP; Anker SD; Dahlström U; Filippatos G; Ponikowski P; Zannad F; Amir O; Chioncel O; Leiro MC; Drozdz J; Erglis A; Fazlibegovic E; Fonseca C; Fruhwald F; Gatzov P; Goncalvesova E; Hassanein M; Hradec J; Kavoliuniene A; Lainscak M; Logeart D; Merkely B; Metra M; Persson H; Seferovic P; Temizhan A; Tousoulis D; Tavazzi L;
    Eur J Heart Fail; 2013 Oct; 15(10):1173-84. PubMed ID: 23978433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.